Puma Biotechnology (PBYI) Announces Underwriters' Full Exercise Of Option To Purchase Additional Shares
2/13/2014 8:58:18 AM
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced that the underwriters for its public offering of 979,592 shares of its common stock at $122.50 per share have elected to exercise in full their option to purchase up to an additional 146,938 shares of common stock at the public offering price, less the underwriting discount. The closing for the additional purchase of 146,938 shares is expected to take place concurrently with the closing for the initial purchase of 979,592 shares on February 14, 2014, subject to customary closing conditions.
Help employers find you! Check out all the jobs and post your resume.
comments powered by